ahlam1399
08-22-2016, 11:52 PM
Pfizer boosts cancer drug roster with $14 billion Medivation deal
(Reuters) - Pfizer Inc , beating out numerous other bidders, said it would buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=-xcSDg5b6ow:15zPFafD0PQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=-xcSDg5b6ow:15zPFafD0PQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=-xcSDg5b6ow:15zPFafD0PQ:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=-xcSDg5b6ow:15zPFafD0PQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=-xcSDg5b6ow:15zPFafD0PQ:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/-xcSDg5b6ow
(Reuters) - Pfizer Inc , beating out numerous other bidders, said it would buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=-xcSDg5b6ow:15zPFafD0PQ:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=-xcSDg5b6ow:15zPFafD0PQ:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=-xcSDg5b6ow:15zPFafD0PQ:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=-xcSDg5b6ow:15zPFafD0PQ:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=-xcSDg5b6ow:15zPFafD0PQ:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/-xcSDg5b6ow